Embed Size (px)
Citation preview
Covered in this Report
• The report includes the present scenario and the growth prospects of the global retinoblastoma market for the period 2015-2019.
• To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of retinoblastoma.
• Technavio's report, Global Retinoblastoma Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.
• It covers the market size and forecast as well as the market segmentation.
• The report includes a discussion of the key vendors operating in this market.
Global Retinoblastoma
Market 2015-2019
USA – CANADA – UK – CHINA – INDIA
Market Overview• Cancer occurs when normal cells transform to evade
the regular cell cycle process.
• Retinoblastoma is a rare eye cancer.
• It occurs in children of age less than 15 years; the disease is common in children younger than five years, especially children less than two years.
• The disease affects the retina and is caused by a mutation in the gene RB1.
• It usually appears in one eye and gradually spreads to the other.
• Technavio's analysts forecast the global retinoblastoma market to grow at a CAGR of 3.57% over the period 2014-2019.
To know more aboutGlobal Retinoblastoma
Market 2015-2019,please mail us at
USA – CANADA – UK – CHINA – INDIA
Key Vendors and Regions
• Baxter
• Bristol-Myers Squibb
• GlaxoSmithKline
• Spectrum Pharmaceuticals
• BioLineRx
• Cellceutix
• Icon Bioscience
• Neotropix
• RXi Pharmaceuticals
View Our Report: Global Retinoblastoma Market 2015-2019
• Americas
• APAC
• EMEA
Vendors Regions
USA – CANADA – UK – CHINA – INDIA
Key Findings
• The competition in the market is low, as there are many small and large vendors offering off-patent generic drugs.
• The patient pool is relatively small, as well.
• However, an increase in the number of cases of retinoblastoma due to public awareness and early disease diagnosis are expected to drive the growth of the market.
• Companies that manufacture and market a drug that can both deliver the drug to the site of action and maximize safety and efficacy profiles will gain a competitive advantage over their peers.
• The major vendors in the market are Bristol-Myers Squibb, Baxter, GlaxoSmithKline, and Spectrum Pharmaceuticals.
USA – CANADA – UK – CHINA – INDIA
Key Questions Answered in Our Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Have a question of your own about this report?
Ask our Analysts
USA – CANADA – UK – CHINA – INDIA
• Decision makers and influencers in sales & marketing, strategy, product and R&D teams rely on research from Technavio. We have a large and growing base of happy customers worldwide. Our customers include technology suppliers, end users, consulting companies, investment firms and research institutes.
• Technavio was founded in 2003 in London. We have about 300 analysts globally. We cover more than 500 technologies across 80 countries. Traditional media such as Forbes Asia and New York Times, along with other web media portals, like to quote us.
About Technavio
Some of our clients include:ACT Global, Flextronics, Huawei Technologies Co, Infosys, Harris Corporation, Infosys, Intercad, Hidaka Precision Tools & Dies Company, Huawei Technologies Co, American Capital, Analysis Group, Netscout, NTT DoCoMo
USA – CANADA – UK – CHINA – INDIA
View Our Report
Global Retinoblastoma Market 2015-2019
95 Pages | SKU: IRTNTR6804
For media enquiries,
please drop us a mail at
For more on the scope of the report, mail us at
Thank You!
Mail us at: [email protected] can visit us at:www.technavio.com
USA – CANADA – UK – CHINA – INDIA
